Pay in 4 interest-free payments of $20.00 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
the introduction of the boronic acid group confers superior oral bioavailability of GLL398 (AUC = 36
InChi: InChI=1S/C27H30F3N9O/c1-17(38-8-10-39(11-9-38)25(40)15-27(28
Smiles: C[C@@H]1CC=CC=CC=CC=C[C@@H](C[C@@H]2O[C@@](O)(C[C@H](O)[C@H]2C(O)=O)C[C@@H](O)C[C@H]2O[C@@H]2C=CC(=O)O1)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](N)[C@@H]1O |t:3
Solubility: DMSO: 6 mg/mL(9
GS5734-metabolite
Foretinib 603oglibose the introduction of the boronicForetinib, also known as XL880 and GSK1363089, is an orally bioavailable small molecule with potential antineoplastic activity. MET VEGFR2 inhibitor GSK1363089 binds to and selectively inhibits hepatocyte growth factor (HGF) receptor c MET and vascular endothelial growth factor receptor 2 (VEGFR2), which may result in the inhibition of tumor angiogenesis, tumor cell proliferation and metastasis. The proto oncogene c MET has been found to be over
US$ 68.00
US$ 61.95
US$ 649.50
US$ 38.00
US$ 1490.00
US$ 425.00
US$ 625.00
US$ 399.50
US$ 875.00
US$ 499.50
US$ 74.00
US$ 74.00
US$ 68.00
US$ 625.00
US$ 325.00
US$ 499.50